MolDX: Oncotype DX Breast Cancer for DCIS (Genomic Health™)

Summary of Evidence Analysis of Evidence General Information Associated Information Sources of Information Bibliography Revision History Information Associated Documents Attachments Related Local Coverage Documents Related National Coverage Documents Public Versions Keywords Local Coverage Determination (LCD) MolDX: Oncotype DX® Breast Cancer for DCIS (Genomic Health™) L36912 Expand All | Collapse All  Email Document  Download  Add to basket Contractor Information Contractor Name Contract Type Contract Number Jurisdiction States LCD Information Document Information LCD ID L36912 LCD Title MolDX: Oncotype DX® Breast Cancer for DCIS (Genomic Health™) Proposed LCD in Comment Period N/A Source Proposed LCD DL36912 Original Effective Date For services performed on or after 03/06/2017 Revision Effective Date For services performed on or after 11/25/2021 Revision Ending Date N/A Retirement Date N/A Notice Period Start Date 01/19/2017 Notice Period End Date 03/05/2017 CPT codes, descriptions, and other data only are copyright 2025 American Medical Association. All Rights Reserved. Fee schedules, relative value units

This contractor will provide limited coverage for the Oncotype DX ® DCIS assay (Genomic Health, Inc., Redwood City, CA) for women diagnosed with DCIS who are planning on having breast conserving surgery and considering adjuvant radiation therapy.